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Introduction {#j_raon-2020-0002_s_001}
============

Up to 50% of the metastatic breast cancer (mBC) patients eventually develop liver metastases which is associated with a poor overall survival ranging from 1--3 years.[@j_raon-2020-0002_ref_001],[@j_raon-2020-0002_ref_002] Liver metastatic breast cancer (LMBC) patients with limited (extra) hepatic disease can obtain a survival benefit from local treatment options, such as surgery and ablation.[@j_raon-2020-0002_ref_003], [@j_raon-2020-0002_ref_004] Unfortunately, most LMBC patients have extended disease whereby systemic treatment by chemotherapy or anti-hormonal therapy, in hormone sensitive breast cancer, is indicated. Systemic treatment with chemotherapy has lengthened overall survival, but haematological, gastrointestinal and neurotoxicity are dose-limiting factors with systemic administration of these agents.[@j_raon-2020-0002_ref_005] Therapies with less systemic toxicity are therefore an attractive treatment option in LMBC patients refractory to systemic chemotherapy.[@j_raon-2020-0002_ref_006]

Several intra-arterial therapies have been applied for LMBC patients, such as radioembolization (Yttrium-90 (^90^Y) resin microspheres), chemo embolization and chemo infusion, reported as effective and safe treatment options.[@j_raon-2020-0002_ref_007], [@j_raon-2020-0002_ref_008], [@j_raon-2020-0002_ref_009] Of these treatments, the best results are reported for intraarterial radioembolization, with a disease control rate of 72--91% and an overall survival of 6.6--13.6 months.[@j_raon-2020-0002_ref_007],[@j_raon-2020-0002_ref_010], [@j_raon-2020-0002_ref_011], [@j_raon-2020-0002_ref_012] For over 15 years, LMBC patients are treated by intra-arterial chemo infusion with mitomycin C (MMC) in our institute whereby disease control is obtained in 58% with low adverse events in a very heavily pre-treated cohort.[@j_raon-2020-0002_ref_009]

Since primary breast cancer is sensitive for both systemic chemotherapy and external beam radiation therapy, LMBC patients might also benefit from the combined treatment of chemo infusion and selective internal radiation therapy (SIRT).

However, the sequential administration of these intra-arterial therapies *e.g*. SIRT and intra-arterial chemo infusion, has not yet been reported. In this pilot study we prospectively analysed the safety and feasibility of the sequential intra-arterial infusion of ^90^Y resin microspheres and MMC in patients refractory to conventional systemic chemotherapy.

Patients and methods {#j_raon-2020-0002_s_002}
====================

This prospective phase I pilot study of 16 patients was approved by the ethics committee of our hospital (S 53657). Patients were included from April 2012 until March 2018. All patients signed a written informed consent. Patient selection was performed by a multidisciplinary tumour board consisting of medical, surgical and radiation oncologists together with pathologists, nuclear medicine physicians and (interventional) radiologists.

In [Table 1](#j_raon-2020-0002_tab_001){ref-type="table"}, the inclusion and exclusion criteria for this pilot study are shown. [Figure 1](#j_raon-2020-0002_fig_001){ref-type="fig"} shows the treatment schedule of ^90^Y SIRT followed by MMC infusion in the different cohorts. The first 3 patients were allocated to cohort A, the second 3 patients to cohort B, the 3 patients thereafter to cohort C and the remaining of the patients in cohort D. Patients first underwent the ^90^Y treatment and in the absence of progression, the sequential intra-arterial hepatic MMC infusions were administrated 8 weeks later.

![Treatment overview of the 16 patients treated with selective internal radiation therapy with Yttrium-90 containing microspheres (^90^Y SIRT) and mitomycin C (MMC) infusion in 4 escalating cohorts.](raon-54-033-g001){#j_raon-2020-0002_fig_001}

###### 

Inclusion and exclusion criteria

  Inclusion criteria                                                  Exclusion criteria
  ------------------------------------------------------------------- ---------------------------------------------------
  Histologically confirmed diagnosis of breast cancer                 Bilirubin level \> 1.5x upper limit normal
  Radiological evidence of liver metastases                           Transaminase (AST/ALT) \> 2.5x upper limit normal
  Liver only or liver predominant with stable extra-hepatic disease   Creatinine \> 1.2x upper limit normal
  Progressive under (multi-line) systemic chemo or hormonal therapy   Glomerular filtration rate \< 60 mL/min/1.73 m^2^
  Eligible for intra-arterial therapy                                 Neutrophils \< 1000/μL
  Age \> 18 years                                                     Thrombocytes \< 100x109/L
  Karnofsky performance \> 70                                         Lung shunt fraction \> 20%
                                                                      Allergy to contrast media
                                                                      Active use of oral anticoagulation

ALT = alanine aminotransferase; AST = aspartate aminotransferase

Radioembolization with Yttrium-90 (^90^Y) resin microspheres {#j_raon-2020-0002_s_002_s_001}
------------------------------------------------------------

All ^90^Y procedures were performed under local anaesthesia by or under direct supervision of an expert interventional radiologist (GM) and nuclear medicine physician (CD). Previously published work describes the details of the ^90^Y treatment.[@j_raon-2020-0002_ref_013] Briefly, patients first underwent a detailed baseline angiogram and embolization of enterohepatic arteries with micro-coils according to the expertise of the interventional radiologist. Technetium-99m-macroaggregated albumin (^99m^TC-MAA) was injected in the target vessels and a planar scintigraphy was performed to determine the lung shunt fraction. Two weeks later patients underwent bi-lobar or uni-lobar injection of ^90^Y resin microspheres (SIR spheres, Sirtex Inc, Cosgrove, Australia) under local anaesthesia. The activity of ^90^Y injected in the patient was calculated based on the body surface area method. In patients where it was possible to use the partition model, the partition model was used instead of the body surface area method. Dependent on the site of lesions, the ^90^Y resin microspheres were injected intra-arterially via a micro catheter to the right and left liver lobe (superselective). A Progreat® micro catheter (Terumo, Europe) or an anti-reflux catheter (Surefire Inc., Westminster, CO, USA) was used for injection of the microspheres. Patients received antiemetics and morphine derivates before ^90^Y injection when required.

Hepatic intra-arterial chemo infusion with MMC {#j_raon-2020-0002_s_002_s_002}
----------------------------------------------

Six to eight weeks after the ^90^Y treatment, patients underwent response assessment by magnetic resonance imaging (MRI) of the liver and a whole body \[[@j_raon-2020-0002_ref_018]F\]-FDG positron emission tomography/ computed tomography scan ([@j_raon-2020-0002_ref_018]F-FDG PET/CT) together with laboratory tests. If patients showed no untreatable progression of disease on MRI and [@j_raon-2020-0002_ref_018]F-FDG PET-CT scan (bases on RECIST criteria 1.1) together with acceptable laboratory results (\> 100x10[@j_raon-2020-0002_ref_009] thrombocytes/L), the intra-arterial chemoinfusion of MMC could be administrated. Six to ten weeks after the ^90^Y procedure, patients received the first infusion of MMC, as previously described by our group.[@j_raon-2020-0002_ref_014] After local anaesthesia, vascular access was obtained by the right common femoral artery and, using a diagnostic 4-French catheter, a micro catheter was placed in the right and left hepatic arteries for injection of MMC in both liver lobes.

Ascending maximal doses of MMC were administrated in different cohorts. Patients were allocated to the MMC cohort before the ^90^Y procedure. The first cohort (A) received one cycle of 6mg MMC, the second cohort (B) received one cycle of 12mg MMC, the third cohort (C) received 2 cycles of 12mg of MMC and the fourth cohort (D) received the standard regime of MMC infusion consisting of a maximum of 6 cycles of each 12mg of MMC. Before and after the MMC infusion laboratory results were taken to determine whether the dose could be tolerated. The dose of MMC was adjusted when thrombocyte count was \< 100x10^9^ thrombocytes/L. In the last cohort, the effect of MMC was radiologically evaluated, by CT or MRI, after every two cycles. If these evaluations showed no further intra- or extra-hepatic disease progression, the patient was rescheduled for the next 2 cycles for a maximum of 6 cycles.

Outcomes {#j_raon-2020-0002_s_002_s_003}
--------

The primary outcomes of this study included the feasibility and safety of MMC infusion after ^90^Y SIRT. The feasibility was defined as the number of patients receiving the MMC infusion after ^90^Y treatment. The safety was determined by the number of grade 3 and higher adverse events after MMC and ^90^Y treatment and documented by the Common Terminology Criteria for Adverse Events version 5.0. For the response assessment the modified response evaluation criteria in solid tumours (mRE-CIST) was used to measure hepatic response by a maximum of two target lesions and categorized into four categories \[Complete Response (CR), Partial Response (PR), Stable Disease (SD) and Progressive Disease (PD)\].[@j_raon-2020-0002_ref_015]

Statistical analysis {#j_raon-2020-0002_s_002_s_004}
--------------------

Patient and pre-treatment characteristics were presented as numbers, percentages and median time with range. Overall survival (OS) was calculated from work-up for ^90^Y treatment until death or loss to follow up by the Kaplan Meier estimates. All analyses were performed in SPSS (IBM Corp, version 25, Armonk, NY).

Results {#j_raon-2020-0002_s_003}
=======

Patient characteristics {#j_raon-2020-0002_s_003_s_001}
-----------------------

[Table 2](#j_raon-2020-0002_tab_002){ref-type="table"} shows the patient characteristics of the 16 treated women. The median time from diagnosis of metastatic breast cancer to start of the study was 28 months (range 7.7--91.0 months). Patients were 26-- 77 (median 59) years old at the start of the study.

###### 

Patient characteristics

  Patient Characteristics                                                N = 16
  ---------------------------------------------------------------------- -------------
  Median months from diagnosis metastatic disease until start of study   28 (8--91)
  Median age at start study in years (range)                             59 (26--77)
  Diagnosis of liver metastasis                                          
  Synchronous                                                            2 (12.5%)
  Metachronous                                                           14 (87.5%)
  Hormone status of liver metastasis (n = 15)                            
  Estrogen receptor (positive)                                           8 (53%)
  Progesterone receptor (positive)                                       8 (53%)
  HER2Neu receptor (negative)                                            15 (100%)
  Triple negative receptor status                                        6 (40%)
  Tumor burden liver                                                     
  \< 25%                                                                 9 (56%)
  25%--50%                                                               6 (38%)
  50%--75%                                                               1 (6%)
  Prior hepatic treatment                                                
  Surgery/Ablation                                                       1 (6.3%)
  Median number of chemotherapy regimens for stage 4 disease             3 (0--8)
  Extra-hepatic sites of metastases                                      
  Yes                                                                    9 (56%)
  No                                                                     7 (44%)
  Number of additional metastatic sites                                  
  1                                                                      5 (31%)
  2                                                                      2 (13%)
  ≥ 3                                                                    2 (13%)
  Location of extrahepatic metastases                                    
  Bone                                                                   5 (31%)
  Lung                                                                   3 (19%)
  Non-locoregional nodes                                                 4 (25%)
  Brain                                                                  2 (13%)

A liver biopsy was taken before start of the study in 15 patients and showed a positive oestrogen receptor in 8 patients, positive progesterone receptor in 8 patients and a negative HER2-neu status in all patients (n = 15). Six patients had a triple negative receptor status. Tumour burden of the liver was \< 25% in 9 patients and \> 25% in 7 patients. Nine patients had extra-hepatic disease with a median of 1 site (range 0--4) and bone (n = 5) as most common site. Before inclusion, the median number of chemotherapy lines in the metastatic phase was 3 regimes consisting of anthracyclines in 75% and taxanes in 81%.

Treatment {#j_raon-2020-0002_s_003_s_002}
---------

[Figure 1](#j_raon-2020-0002_fig_001){ref-type="fig"} shows a treatment overview of the 16 patients. All 16 patients underwent the ^90^Y procedure whereby pre-embolization of extra hepatic arteries was performed in 14/16 patients. A median dose of 1.68 GBq (range 1.043--2.140) was inserted in both liver lobes (n = 14) or one liver lobe (n = 2). At response evaluation five patients showed extra-hepatic disease progression, of whom, three patients were excluded for additional MMC infusion and two patients received the sequential MMC infusion, but with additional therapy of Exemestane (Aromasin®) for stabilization of their extra-hepatic disease. One patient was hospitalized after ^90^Y SIRT for 2.5 weeks because of the side effects of the ^90^Y treatment and excluded from further treatment.

Median time between ^90^Y SIRT and first MMC infusion was 2.1 months (range 1.7--12.8 months). In one patient an interval of 12.8 months occurred, because of PD in the liver after ^90^Y treatment. This patient first received systemic chemotherapy and after progression during this systemic chemotherapy the MMC infusion was administrated. A total of 12 patients were treated in four different cohorts of MMC doses after the ^90^Y treatment ([Figure 1](#j_raon-2020-0002_fig_001){ref-type="fig"}). In cohort D, the maximum of 6 cycles of 12 mg MMC was administrated in 2 patients. In the other four patients the dose was adjusted (n = 2) and discontinued (n = 2) due to hematologic toxicity (thrombocytopenia) and disease progression.

Adverse events {#j_raon-2020-0002_s_003_s_003}
--------------

[Table 3](#j_raon-2020-0002_tab_003){ref-type="table"} shows the adverse events after the ^90^Y SIRT and MMC infusion. After the ^90^Y treatment one grade 3 adverse event occurred, consisted of a gastric ulcer treated with proton pump inhibitors and hospitalization. The most common grade 1/2 adverse events after ^90^Y SIRT were pain 7/16, nausea

###### 

Number of grade 1 (G1), grade 2 (G2) and grade 3 (G3) adverse events after treatment of selective internal radiation therapy by ^90^Y labeled microspheres infusion (^90^Y SIRT) and mitomycin C (MMC) infusion within 30 days. No grade 3 adverse events occurred after MMC infusion

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
  Treatment                              ^90^Y SIRT   MMC\        MMC\        MMC\        MMC\                                                      
                                                      Cohort A\   Cohort B\   Cohort C\   Cohort D\                                                 
                                                      1x6mg       1x12mg      2x12 mg     max 6x12mg                                                
  -------------------------------------- ------------ ----------- ----------- ----------- ------------ -------- -------- -------- -------- -------- --------
  **Adverse events**                     **G1**       **G2**      **G3**      **G1**      **G2**       **G1**   **G2**   **G1**   **G2**   **G1**   **G2**

  **Clinical**                                                                                                                                      

  Fatigue                                2/16         \-          \-          \-          \-           \-       \-       3/3      \-       2/6      \-

  Pain                                   5/16         2/16        \-          \-          \-           \-       \-       \-       \-       1/6      \-

  Nausea                                 3/16         2/16        \-          \-          \-           \-       \-       \-       \-       1/6      \-

  Emesis                                 2/16         2/16        \-          \-          \-           \-       \-       \-       \-       1/6      \-

  Gastrointestinal ulcer                 \-           4/16        1/16        \-          \-           \-       \-       \-       \-       \-       \-

  **Biochemical**                                                                                                                                   

  Leukopenia                             2/16         \-          \-          \-          \-           \-       \-       2/3      \-       4/6      2/6

  Thrombocytopenia                       3/16         1/16        \-          1/2         \-           1/1      \-       3/3      \-       4/6      2/6

  Anaemia                                \-           \-          \-          \-          \-           \-       \-       \-       \-       4/6      \-

  Increased aspartate aminotransferase   5/16         1/16        \-          \-          \-           \-       \-       \-       \-       2/6      \-

  Increased alanine aminotransferase     3/16         1/16        \-          \-          \-           \-       \-       \-       \-       1/6      \-

  Increased bilirubin                    \-           \-          \-          \-          \-           \-       \-       1/3      1/3      \-       \-

  Increased alkaline phosphatase         2/16         1/16        \-          \-          \-           \-       \-       1/3      \-       2/6      \-

  Decreased eGFR                         \-           1/16        \-          \-          \-           \-       \-       \-       \-       \-       \-

  Increased gamma-glutamyl transferase   4/16         1/16        \-          \-          \-           \-       \-       1/3      \-       4/6      \-
  ----------------------------------------------------------------------------------------------------------------------------------------------------------

eGFR = estimated glomerular filtration rate

5/16 and ulcer 4/16. An elevation in liver function test (aspartate, alanine and gamma-glutamyl transferase) was seen in 8/16 patients.

No grade 3 or higher adverse events occurred after MMC infusion. The most common grade 1/2 adverse event was thrombocytopenia in 11/12 patients and leukopenia in 8/12 patients.

Response, follow up and survival {#j_raon-2020-0002_s_003_s_004}
--------------------------------

Response evaluation of the liver after 6 to 8 weeks after ^90^Y treatment (n = 16) revealed PR in 10 patients and SD in 6 patients ([Figure 2](#j_raon-2020-0002_fig_002){ref-type="fig"}). Extra hepatic response evaluation showed PD in 5 patients and SD in 11 patients. Additional hepatic response of MMC infusion after ^90^Y treatment was PR in 4/12 patient, SD in 5/12 patients and PD in 3/12 patients.

![Hepatic response on magnetic resonance imaging (MRI) before ^90^Y treatment **(A)**, after ^90^Y treatment **(B)** and after 2 cycles of MMC infusion **(C)**. C is a partial response relative to A. Arrows indicate the liver metastases.](raon-54-033-g002){#j_raon-2020-0002_fig_002}

After the study, nine patients were eligible to receive systemic chemotherapy and one patient was eligible for surgery and underwent a segmentectomy. The median OS was 12.6 months (95% CI 10.23--15.0).

Discussion {#j_raon-2020-0002_s_004}
==========

Intra-arterial therapy is a treatment option in patients with chemo-refractory liver dominant metastatic breast cancer.^6^ In our institute MMC infusions are performed for almost 20 years for chemo refractory LMBC whereby a disease control of 58% is obtained with low grade adverse events.^9^ In the present study we investigated whether MMC infusion is feasible and safe after ^90^Y SIRT.

The sequential treatment of ^90^Y followed by MMC was possible in 75% (12/16) of the enrolled patients. Only low-grade adverse events (grade 1 and 2) were observed after the MMC infusions. In addition, the gradual escalation of the MMC infusions, ranging from 6 mg in 1 cycle to a maximum of 72 mg in 6 cycles, caused no additional adverse events.

During the regular MMC protocol of our institute, patients can receive a maximum of 72 mg in 6 cycles whereby close monitoring is performed to adjust, postpone or stop the MMC infusion after each cycle.^9^ In current study, the same protocol was followed in the last cohort, subsequently 4 patients did not receive all 6 MMC cycles. Thus, this pilot shows that the regular protocol of MMC can be followed after prior treatment with ^90^Y. Patients maintained their performance status after the sequential treatments, and so 9/12 patients were eligible for systemic therapy afterwards and 1/12 even for hepatic surgery. Therefore, this combination treatment can be used as a drug holiday from systemic treatment.

We did observe a high number of gastrointestinal ulcers after ^90^Y SIRT (n = 5, 31%). All these patients underwent pre-embolization and received a bilobar treatment in the left and right hepatic artery. Despite these precautions, the ulcers occurred probably due to reflux and non-target deposition of the ^90^Y resin microspheres which is a known risk of ^90^Y treatment for LMBC.[@j_raon-2020-0002_ref_016] After the introduction of an anti-reflux catheter in the last 6 patients, no more ulcers occurred. According to the literature, several factors are associated with reflux of ^90^Y resulting in gastrointestinal ulcering, namely prior administration of monoclonal antibodies (*i.e*. bevacuzimab, trastuzumab), the type of ^90^Y micro-spheres and the dose of ^90^Y.[@j_raon-2020-0002_ref_010], [@j_raon-2020-0002_ref_017] In the present study no correlations were found for prior monoclonal antibodies treatment and the dose of ^90^Y with the development of gastrointestinal ulcers. The development of the gastrointestinal ulcers in the current study was probably caused by several pretreatment and treatment related factors. The use of the anti-reflux catheter showed improvement with no further reported gastrointestinal ulceration. Therefore, caution is needed in future studies.

The median OS of radioembolization in LMBC patients ranges from 6.6--13.6 months, which is in line with the median OS of 12.6 in this study.[@j_raon-2020-0002_ref_010], [@j_raon-2020-0002_ref_011],[@j_raon-2020-0002_ref_018], [@j_raon-2020-0002_ref_019], [@j_raon-2020-0002_ref_020] The median OS was higher compared to earlier studies where patients received only MMC infusion (12.6 versus 7.6 months).[@j_raon-2020-0002_ref_009],[@j_raon-2020-0002_ref_014] However, the inclusion criteria for this study were more strict than our routine indications for MMC infusion. Consequently, patients had less extensive local and extra hepatic disease with a better performance status compared to our previous reported cohort of patients treated with MMC infusion only.

The main limitation of this study consists of small patient number in the cohorts and the long inclusion period.

Conclusions {#j_raon-2020-0002_s_005}
===========

In conclusion, the sequential treatment of intra-arterial infusion of MMC after ^90^Y therapy is feasible with limited low-grade adverse events after MMC. The regular MMC protocol can be followed with adjustment of MMC dose based on clinical, radiological and biochemical parameters. However, caution is needed to prevent reflux after ^90^Y SIRT in LMBC patients. Further research is needed to show whether the combination of ^90^Y and MMC has a benefit over the treatment of MMC or ^90^Y alone in LMBC patients.
